

What we claim is:

1. A composition comprising a cationic liposome containing a cationic lipid, phosphatidylcholine and cholesterol.
2. A composition of claim 1 wherein the liposome contains an antisense oligonucleotide sequence.
3. A composition of claim 2 wherein the antisense sequence is a raf oligodeoxynucleotide.
4. A composition of claim 3 wherein the antisense sequence is of the formula 5'-GTGCTCCCATTGATGC-3' wherein only the terminal sequences are phosphorothioated.
5. A composition of claim 1 in a pharmaceutically acceptable carrier.
6. A composition of claim 4 in a pharmaceutically acceptable carrier.
7. A composition of claim 1 wherein the pharmaceutically acceptable carrier is isotonic.
8. A composition of claim 4 wherein the pharmaceutically

acceptable carrier is a buffered, isotonic solution.

9. A method of radiosensitizing tumor tissue by administration of a radiosensitizing effective amount of at least one antisense oligonucleotide of no more than 40 bases containing the sequence 5'-GTGCTCCATTGATGC-3'.
10. A method of claim 9 wherein the oligonucleotide is phosphorothioated at only the end nucleotides.
11. A method of claim 9 wherein the oligonucleotide is phosphorothioated at only the end nucleotides.
12. A method of claim 9 wherein the oligonucleotide is administered intravenously.
13. A method of claim 9 wherein the oligonucleotide is administered directly to the target tissue.
14. A method of claim 9 wherein the oligonucleotide is administered into the arterial supply to the target tissue.
15. A method of claim 9 wherein the oligonucleotide is of the formula 5'-GTGCTCCATTGATGC-3' and only the end bases only are phosphorothioated.

16. A composition of matter comprising liposomes containing the sequence 5'-GTGCTCCATTGATGC-3' in a pharmaceutically acceptable carrier.
17. A composition of claim 1 wherein the cationic lipid is dimethyldioctadecyl ammonium bromide.